Achalasia: outcome of patients treated with intrasphincteric injection of botulinum toxin.

Abstract

This multicentre series confirms that intrasphincteric injection of BT is a safe procedure, resulting in clinical improvement in 60% of patients with achalasia at six months. The therapeutic role of BT in achalasia needs further evaluation with regard to other alternatives.